Authors

Latest:

Dr. O'Connor on Recent FDA Approvals in MCL

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

Owen O'Connor, MD, PhD

Latest:

Dr. O'Connor on Treatment Options Following Ibrutinib Progression in MCL

Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses treatment options following progression on ibrutinib (Imbruvica) for patients with mantle cell lymphoma (MCL).

P. Cosmo Smith, MBA

Latest:

Cosmo Smith on The Breakthrough Oncology Accelerator Flagship Program

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.

Pablo Ferraro, MD

Latest:

Dr. Ferraro on the Use of Molecular Profiling in Pancreatic Cancer

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Pablo Valderrabano, MD,

Latest:

Dr. Valderrabano on Understanding Cancer Risk in Indeterminate Thyroid Nodules

Pablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.

Padmanee Sharma, MD, PhD

Latest:

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Pallawi Torka, MD

Latest:

Dr. Torka on BTK Inhibitors Available for Patients With R/R MCL

Pallawi Torka, MD, discusses the BTK inhibitors available for treatment of patients with relapsed/refractory mantle cell lymphoma.

Pam Harrison

Latest:

IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Pamela Blair Allen, MD, MSc

Latest:

Dr. Allen on Treatment Options in Advanced-Stage Hodgkin Lymphoma

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

Pamela L. Kunz

Latest:

Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

Pamela L. Kunz, MD

Latest:

Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETs

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

Pamela L. Kunz, MD, Stanford

Pamela Munster, MD

Latest:

Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Pamela N. Munster, MD

Latest:

Dr. Munster on Developing Biosimilars

Pamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.

Pamela R. Soulos, MPH

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Pamela S. Becker, MD, PhD

Latest:

Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AML

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.

Panagiotis A. Konstantinopoulos, MD

Latest:

Dr. Konstantinopoulos on the Phase III Results of the JAVELIN 200 Trial in Ovarian Cancer

Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.

Panagiotis A. Konstantinopoulos, MD, PhD

Latest:

Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

Panayiotis S. Savvides, MD

Latest:

Dr. Savvides on the Risk of COVID-19 in Patients With Cancer

Panayiotis S. Savvides, MD, discusses COVID-19 precautions for patients with lung cancer.

Panelists Francis P. Arena, MD, NYU Langone